The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
Subscribe To Our Newsletter & Stay Updated
